Analyst Price Targets — SITC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 10:48 am | — | Piper Sandler | $3.50 | $3.31 | TheFly | Site Centers price target lowered to $3.50 from $5 at Piper Sandler |
| July 21, 2026 11:04 am | — | Piper Sandler | $5.00 | $4.41 | TheFly | Site Centers price target lowered to $5 from $6 at Piper Sandler |
| January 5, 2026 11:52 am | Alexander Goldfarb | Piper Sandler | $8.00 | $6.40 | TheFly | Site Centers price target lowered to $8 from $10 at Piper Sandler |
| October 22, 2025 10:42 am | — | Piper Sandler | $12.00 | $8.88 | TheFly | Site Centers price target lowered to $12 from $16 at Piper Sandler |
| October 2, 2024 5:27 am | Dori Kesten | Wells Fargo | $19.00 | $17.06 | TheFly | Site Centers downgraded to Equal Weight from Overweight at Wells Fargo |
| September 25, 2024 7:48 am | Todd Thomas | KeyBanc | $9.60 | $9.52 | StreetInsider | KeyBanc Reiterates Overweight Rating on SITE Centers Corp. (SITC) |
| September 19, 2024 6:51 am | Simon Yarmak | Stifel Nicolaus | $10.44 | $9.38 | TheFly | Site Centers price target raised to $65.25 from $65 at Stifel |
| August 28, 2024 8:32 am | Samir Khanal | Evercore ISI | $10.24 | $9.76 | TheFly | Site Centers price target raised to $64 at Evercore ISI |
| August 28, 2024 5:42 am | Dori Kesten | Wells Fargo | $10.88 | $9.76 | TheFly | Site Centers price target raised to $68 from $64 at Wells Fargo |
| July 31, 2024 6:52 am | Alexander Goldfarb | Piper Sandler | $18.00 | $16.01 | TheFly | Site Centers price target raised to $18 from $16 at Piper Sandler |
Latest News for SITC
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of DTP Interests and Special Common Distribution.
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its…
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from…
Site Centers (NYSE: SITC - Get Free Report) and Deutsche Bank Aktiengesellschaft (NYSE: DB - Get Free Report) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends. Insider and Institutional Ownership 88.7% of Site
SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SITC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.